Clinical Trials Sponsored by Astellas Pharma Korea, Inc.

Total 1241 results

Astellas Pharma Inc

Completed

Multiple Oral Administration of ASP7991 to Non-elderly Male Subjects

Healthy | Pharmacokinetics of ASP7991

Japan
Astellas Pharma Inc

Completed

To Evaluate if Multiple Doses of Rifampicin Change the Blood Concentration of YM150 (Darexaban)

Healthy Subjects | Pharmacokinetics of Darexaban and Metabolites

France
Astellas Pharma Inc

Completed

To Evaluate Whether Naproxen and Darexaban (YM150) Interact in Their Effects

Healthy Subjects | Pharmacodynamic Interaction

France
Astellas Pharma Inc

Completed

A Study to Evaluate the Safety and Efficacy of YM150 in Patients With Knee Replacement Surgery (PEARL)

Arthroplasty, Replacement, Knee

United States, Canada
Astellas Pharma Inc

Completed

To Evaluate Whether Acetyl Salicylic Acid (Aspirin), the Combination of Aspirin and Clopidogrel and Darexaban (YM150) Interact in Their Effects

Healthy Subjects | Pharmacodynamic Interaction

France
Astellas Pharma Inc

Completed

Safety, Tolerability and Efficacy Study of the New Medication ASK8007 to Treat Patients With Rheumatoid Arthritis

Rheumatoid Arthritis

United Kingdom, Belgium, Spain, Netherlands, Ireland, Hungary
Astellas Pharma Inc

Completed

A Clinical Study to Investigate the Efficacy, Safety and Pharmacokinetics of ASP3652 in Patients With Chronic Abacterial Prostatitis / Chronic Pelvic Pain Syndrome (CP/CPPS) (AZURE)

Chronic Pelvic Pain Syndrome | Chronic Abacterial Prostatitis

Czech Republic, Germany, Latvia, Lithuania, Poland, Spain
Astellas Pharma Inc

Completed

An Open-Label Study of the Safety and Pharmacokinetics of Repeated-Dose Micafungin in Neonates

Candida

United States
Astellas Pharma Inc

Terminated

Study Comparing the Safety of ASP2151 to Valacyclovir and Placebo in Healthy Volunteers

Safety of ASP2151

United States
Astellas Pharma Inc

Completed

A Study to Evaluate Absorption, Distribution and Elimination of Mirabegron After Oral Administration to Non-elderly Healthy Chinese Subjects

Healthy Subjects | Plasma Concentration of Mirabegron

Japan
Astellas Pharma Inc

Completed

A Study of the Safety and Tolerance of Regadenoson in Subjects With Asthma or Chronic Obstructive Pulmonary Disease

Coronary Artery Disease | Pulmonary Disease, Chronic Obstructive | Asthma

United States
Astellas Pharma Inc

Completed

Study to Evaluate the Immune Response to Pneumococcal Vaccine in Alefacept-treated Adults With Chronic Plaque Psoriasis

Chronic Plaque Psoriasis

United States, Canada
Astellas Pharma Inc

Completed

Direct Factor Xa Inhibitor YM150 for Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation

Atrial Fibrillation

Taiwan, Japan, Korea, Republic of, New Zealand, Singapore, South Africa, Thailand, Australia, Hong Kong, Malaysia
Astellas Pharma Inc

Completed

A Single Oral Dose Study of ASP015K in Healthy Volunteers Assessing the Relative Bioavailability Across Three Tablet Strengths From a New Formulation of ASP015K

Healthy Subjects | Bioavailability of ASP015K | Pharmacokinetics of ASP015K

United States
Astellas Pharma Inc

Completed

A Study to Compare Early Steroid Withdrawal and Long-Term Steroid Maintenance Therapy in Kidney Transplant Patients

Renal Transplantation

United States
Astellas Pharma Inc

Completed

A Study to Assess the Effect of ASP1941 and Mitiglinide on Their Plasma Concentration

Healthy | Pharmacokinetics of ASP1941 | Pharmacokinetics of Mitiglinide

Japan
Astellas Pharma Inc

Completed

A Study to Compare Oral Absorption of YM060 Between Orally-disintegrating Tablet and Conventional Tablet Under With Water Intake

Healthy | Plasma Concentration of YM060

Japan
Astellas Pharma Inc

Completed

A Study to Evaluate Efficacy and Safety of Zolpidem Modified Release Formulation in Insomnia Patients

Sleep Initiation and Maintenance Disorders | Primary Insomnia

Taiwan
Astellas Pharma Inc

Completed

A Study to Evaluate Safety of Multiple Dose of ASP0456 in Healthy Subjects

Healthy | Pharmacokinetics of ASP0456

Japan
Astellas Pharma Inc

Completed

A Study to Assess the Bioavailability of ASP015K

Healthy

United Kingdom
Astellas Pharma Inc

Completed

Pharmacokinetic Interaction Study to Assess the Effect of ASP015K on Mycophenolate Mofetil in Healthy Volunteers

Healthy Subjects | Drug Interactions | Pharmacokinetics of ASP015K

United States
Astellas Pharma Inc

Completed

First in Men Study of Single Oral Doses of ASP1941 in Healthy Subjects

Healthy

United Kingdom
Astellas Pharma Inc

Completed

A Safety and Pharmacokinetics Study of ASP0456 in Healthy Subjects

Healthy | Pharmacokinetics of ASP0456

Japan
Astellas Pharma Inc

Completed

A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy

Erectile Dysfunction | Prostate Cancer

United States
Astellas Pharma Inc

Completed

A Study to Evaluate the Drug Interaction of ASP015K and Tacrolimus

Healthy | Pharmacokinetics of ASP015K and Tacrolimus

United States
Astellas Pharma Inc

Completed

Safety, Tolerability and Pharmacokinetic Study of ASP1517 in Healthy Non-elderly Male Volunteers

Healthy Volunteers

Japan
Astellas Pharma Inc

Completed

A Study to Assess the Effect of YM150 for Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery

Venous Thromboembolism

Japan
Astellas Pharma Inc

Completed

Prevention of Venous Thromboembolism in Subjects Undergoing Hip Fracture Surgery or Surgery in the Lower Extremities

Venous Thromboembolism

Japan
Astellas Pharma Inc

Completed

Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement Surgery

Venous Thromboembolism

Japan, Korea, Republic of, Taiwan, Thailand
Astellas Pharma Inc

Completed

A Pharmacokinetic Study to Investigate the Effect of Food on the Pharmacokinetics of YM150

Healthy | Pharmacokinetics of YM150

Japan
Astellas Pharma Inc

Completed

A Study to Characterize the Effect on the Pharmacokinetics of ASP1941 and Sitagliptin When Given Together to Healthy Subjects

Healthy | Pharmacokinetics of ASP1941

United States
Astellas Pharma Inc

Completed

A Clinical Pharmacological Study of YM155 After Intravenous Infusion in Patients With Advanced Cancer

Cancer

Hungary
Astellas Pharma Inc

Completed

Relative Bioavailability Study of Solifenacin Succinate Liquid Suspension (Fed and Fasting) Versus VESIcare Tablet (Fasting) in Healthy Volunteers

Healthy Volunteers | Pharmacokinetics of Solifenacin Succinate | Bioavailability of Solifenacin Succinate

United States
Astellas Pharma Inc

Completed

Study of Tacrolimus Immunosuppressive Therapy After Kidney Transplantation

Renal Insufficiency, Chronic | Kidney Failure, Chronic | Kidney Transplantation

Russian Federation
Astellas Pharma Inc

Completed

A Safety and Efficacy Study With YM543 in Type 2 Diabetes Mellitus Subjects

Diabetes Mellitus Type 2

Russian Federation
Astellas Pharma Inc

Completed

A Study to Compare the Conversion to Prograf® (Tacrolimus) to the Continuation of Cyclosporine in Patients at Risk for Chronic Renal Allograft Failure (CRAF)

Kidney Transplantation | Graft Rejection

United States
Astellas Pharma Inc

Completed

A Study to Assess Efficacy, Safety and Pharmacokinetics of a Tacrolimus New Oral Formulation (MR4) in BMT Recipients

Bone Marrow Transplantation | Graft Versus Host Disease | Graft-Versus-Host Disease | Graft-Vs-Host Disease

Japan
Astellas Pharma Inc

Completed

A Study of IMAB362 in Japanese Subjects With Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma

Gastric Cancer | Gastro-esophageal Junction (GEJ) Cancer

Japan
Astellas Pharma Inc

Terminated

A Study to Evaluate ASP0367 in Participants With Primary Mitochondrial Myopathy (MOUNTAINSIDE)

Primary Mitochondrial Myopathy

United States
Astellas Pharma Inc

Terminated

A Study to Assess the Safety, Tolerability and Preliminary Efficacy of ASP0367 (MA-0211) in Pediatric Male Participants With Duchenne Muscular Dystrophy (DMD)

Duchenne Muscular Dystrophy (DMD)

United States
Astellas Pharma Inc

Completed

Study of ASP1948, Targeting an Immune Modulatory Receptor, in Japanese Patients With Advanced Solid Tumors

Locally Advanced (Unresectable) or Metastatic Solid Tumor Malignancies

Japan
Astellas Pharma Inc

Completed

A Study to Evaluate the Efficacy of FK949E in Bipolar Disorder Patients With Major Depressive Episodes

Bipolar Disorder

Japan
Astellas Pharma Inc

Completed

Study of ASP8374, an Immune Checkpoint Inhibitor, in Japanese Patients With Advanced Solid Tumors

Advanced Solid Tumors

Japan
Astellas Pharma Inc

Completed

A Study to Continue ASP015K Treatment to Rheumatoid Arthritis Patients Who Completed Phase IIb Study or Phase III Study of ASP015K

Arthritis, Rheumatoid

Japan, Korea, Republic of, Taiwan
Astellas Pharma Inc

Completed

A Survey for Long-term Use of Prograf Capsules in Patient With Interstitial Pneumonia

Interstitial Pneumonia Associated With Polymyositis/Dermatomyositis

Japan
Astellas Pharma Inc

Completed

Phase III Study to Evaluate the Efficacy and Safety of ASP0456 in Patients With Constipation Predominant Irritable Bowel Syndrome

Irritable Bowel Syndrome With Constipation (IBS-C)

Japan
Astellas Pharma Inc

Completed

A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)

Ovarian Cancer | Solid Tumors

United States, United Kingdom, Australia, Canada, Switzerland, Czechia, Italy, Poland, Romania, Russian Federation
Astellas Pharma Inc

Completed

A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®)

Advanced Solid Tumors

United States, United Kingdom
Astellas Pharma Inc

Completed

A Study to Evaluate the Efficacy and Safety of ASP5094 in Patients With Rheumatoid Arthritis on Methotrexate

Rheumatoid Arthritis (RA)

Japan
Astellas Pharma Inc

Completed

Study to Find Maintenance Dose for Periodic Administration of ASP3550

Prostatic Neoplasms

Japan

3

Subscribe